FibroBiologics Research Development from 2010 to 2026
| FBLG Stock | 0.40 0.06 17.65% |
Research Development | First Reported 2010-12-31 | Previous Quarter 5.2 M | Current Value 5.4 M | Quarterly Volatility 1.7 M |
Check FibroBiologics Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among FibroBiologics Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 454.6 K, Selling General Administrative of 11.1 M or Other Operating Expenses of 16.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 22.72. FibroBiologics financial statements analysis is a perfect complement when working with FibroBiologics Common Valuation or Volatility modules.
FibroBiologics | Research Development | Build AI portfolio with FibroBiologics Stock |
Latest FibroBiologics Common's Research Development Growth Pattern
Below is the plot of the Research Development of FibroBiologics Common Stock over the last few years. It is FibroBiologics Common's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in FibroBiologics Common's overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
FibroBiologics Research Development Regression Statistics
| Arithmetic Mean | 1,559,834 | |
| Geometric Mean | 1,046,257 | |
| Coefficient Of Variation | 110.40 | |
| Mean Deviation | 1,323,629 | |
| Median | 669,000 | |
| Standard Deviation | 1,722,057 | |
| Sample Variance | 3T | |
| Range | 4.9M | |
| R-Value | 0.74 | |
| Mean Square Error | 1.4T | |
| R-Squared | 0.54 | |
| Significance | 0.0007 | |
| Slope | 251,725 | |
| Total Sum of Squares | 47.4T |
FibroBiologics Research Development History
About FibroBiologics Common Financial Statements
FibroBiologics Common stakeholders use historical fundamental indicators, such as FibroBiologics Common's Research Development, to determine how well the company is positioned to perform in the future. Although FibroBiologics Common investors may analyze each financial statement separately, they are all interrelated. For example, changes in FibroBiologics Common's assets and liabilities are reflected in the revenues and expenses on FibroBiologics Common's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in FibroBiologics Common Stock. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research Development | 5.2 M | 5.4 M |
Currently Active Assets on Macroaxis
When determining whether FibroBiologics Common is a strong investment it is important to analyze FibroBiologics Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics Common's future performance. For an informed investment choice regarding FibroBiologics Stock, refer to the following important reports:Check out the analysis of FibroBiologics Common Correlation against competitors. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics Common. If investors know FibroBiologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.